MGLL and early-onset autosomal dominant Alzheimer disease: The endocannabinoid (eCB) ligand 2-arachidonoylglycerol (2-AG) is degraded primarily by monoacylglycerol lipase (MAGL), and the selective MAGL inhibitor JZL184 has exhibited neuroprotective effects in mouse models of Alzheimer’s disease [8] and PD [9].